Ocumetics Technology Corp (TSE:OTC) has released an update.
Ocumetics Technology Corp. has announced the successful development of a new injector delivery system, designed by Swiss manufacturer Medicil, for the Ocumetics Accommodative Intraocular Lens, aiming to improve cataract surgery outcomes. This marks a key step towards their first-in-human study slated for early 2025, which will assess the safety and efficacy of the lens in a clinical setting.
For further insights into TSE:OTC stock, check out TipRanks’ Stock Analysis page.
